|
NOROVIRUS
Norovirus is the leading cause of infectious gastroenteritis in developed countries worldwide. Outbreaks of the virus are very common in long-term care facilities, hospitals and schools, and complications related to the infection can include organ dysfunction or even death. LigoCyte has developed a first-in-class VLP vaccine against norovirus that is currently undergoing human testing.
|
|
|
|
|
INFLUENZA
Influenza is a common virus that causes respiratory infections. Each year in the United States, up to one-fifth of the population is infected with influenza, leading to more than 200,000 hospitalizations and 36,000 deaths. LigoCyte’s VLP vaccine against influenza has demonstrated a high degree of protection in disease models. |
|
|
|
|
COMPANY
LigoCyte is a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications. The company’s virus-like particle (VLP) vaccine technologies support products that induce robust immune responses to prevent serious infections. |
|
|
|
